The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
The UK's NICE has issued final guidance on the use of Sarclisa (isatuximab), from Sanofi, administered as an intravenous infusion, plus pomalidomide and dexamethasone, which is recommended for use within the Cancer Drugs Fund (CDF) as an option for treating relapsed and refractory multiple myeloma in adults.
Genmab announced that Janssen Pharmaceutica has submitted a variation to the Marketing Authorization to the European Medicines Agency (EMA) seeking...
The FDA has added more data to the indication of Kyprolis with dexamethasone �specifically, data that showed Kyprolis from Amgen,,...
The purpose of this study is to determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM).
Genmab announced that the European Commission (EC) has granted a marketing authorization for Darzalex (daratumumab) in combination with lenalidomide and...
Janssen Biotech announced that the FDA has approved the immunotherapy Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the...
Celgene Corporation has announced it has fulfilled the accelerated approval requirements for Pomalyst (pomalidomide) based on results from MM-003, an...
The FDA has granted approval for Empliciti (elotuzumab), from BMS/Abbvie, in combination with two other therapies to treat people with...
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...